State College, PA (PRWEB) August 18, 2014
INDIGO Biosciences, a research products and services company focused on nuclear receptor screenings, announced today that it has released new cell-based Aryl Hydrocarbon Receptor (AhR) reporter assay kits. The Aryl Hydocarbon Recepctor (AhR) Assay employs the luciferase reporter gene technology, and is used for screening test samples to quantify any functional activity that they may exert against human AhR.
INDIGO Biosciences offers a comprehensive menu of nuclear receptor screening products and services, as well as nonhuman nuclear receptor assays, functional assays and custom assay development. The AhR Assay is a natural extension of the work that INDIGO is best known for.
“This new assay represents a significant addition to INDIGO’s research services,” said Dr. Jack Vanden Heuvel, Chief Scientific Officer. “While AhR is not technically a member of the nuclear reception superfamily, it shares many of the same attributes and fields of application. For example, like the xenobiotic-sensing nuclear receptors, in the drug development arena the activation of AhR has major implications for drug efficacy and the potential for toxicity.”
INDIGO’s AhR reporter cells are prepared using their proprietary CryoMite™ process, which provides long-term cryo-preservation of cells for shipping and storage, allowing on-demand use of the products in their customers’ labs.
The Human AhR assay kit is an all-inclusive system that includes two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent and a cell culture-ready assay plate. “Our AhR assay kit is a convenient, quick, and reliable way to quantify the activation or inactivation status of human AhR in response to test compound exposure,” added Vanden Huevel. “The assay is very sensitive, and provides researchers with important information relevant to drug development and toxicologic assessments.”
About INDIGO Biosciences
INDIGO Biosciences, Inc. was founded in State College, Pennsylvania in 2005. As a privately held biosciences company, INDIGO offers both research products and services focused on nuclear receptors. INDIGO provides high-quality, confidential screening services and assay kits for the pharmaceutical, biotechnology, agri-business, nutriceutical industries, government research agencies, and academic researchers.